Over‐expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Polycomb group protein EZH2 and Bmi1 are reportedly involved in the progression of malignant tumours. We examined the participation of EZH2 in multi‐step cholangiocarcinogenesis in hepatolithiasis with respect to tumour suppressor gene p 16 INK4a . We examined 20 hepatolithiatic livers with intrahepatic cholangiocarcinoma (ICC) and 10 histologically normal livers. Neoplastic biliary lesions were classified into biliary intraepithelial neoplasm (BilIN‐1, 2 and 3) and invasive carcinoma. We selected 15 foci of invasive carcinoma, 8 BilIN‐3 (carcinoma in situ ), 12 BilIN‐2 (high‐grade dysplasia), 32 BilIN‐1 (low‐grade dysplasia) and 37 non‐neoplastic biliary epithelia from these livers. Expression of p16 INK4a , EZH2 and Bmi1 were surveyed in these foci. P16 INK4a promoter methylation was examined in microdissected tissues. Taking advantage of two cell lines of CC (HuCTT‐1 and TFK‐1) and small interfering RNA ( si RNA), the effects of the knockdown of EZH2 on p16 INK4a methylation of CC cells were examined. Expression of p16 INK4a , which was frequent in BilIN1, was decreased in BilIN‐2/3 and invasive carcinoma, while EZH2 expression showed step‐wise increase from BilIN‐1, ‐2 and ‐3 to invasive carcinoma ( p < 0.01). P16 INK4a promoter hypermethylation was related to aberrant expression of EZH2. The knockdown of EZH2 in cultured CC cells decreased p16 INK4a methylation and decreased binding of EZH2 to the p16 INK4a gene promoter. The latter suggested that direct binding of EZH2 is involved in the regulation of the p16 INK4a gene. Our data suggest that over‐expression of EZH2 may induce hypermethylation of p16 INK4a promoter followed by decreased expression of p16 INK4a in the multi‐step cholangiocarcinogenesis through intraepithelial neoplasm in hepatolithiasis. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379 · cited 1×
“There is increasing evidence that multiple mechanisms involving cell-regulatory genes are operative in suppression of oncogene activation and also in inhibition of progression of malignant tumours [16].”
BackgroundThe Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Kleer, C. G., Cao, Q., Varambally, S., Shen, R., Ota, I., Tomlins, S. A., Ghosh, D., Sewalt, R. G. A. B., Otte, A. P., Hayes, D. F., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1933744100 · Cited by 1,649
Jacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580 · cited 3×
“EZH2 is the chromatin-modifying enzyme and interacts with the pathways of key elements that control cell growth and proliferation, such as the Rb and p16 INK4a genes [9,11].”
BackgroundGlinsky, G. V., Berezovska, O., & Glinskii, A. B. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23412 · Cited by 916 · cited 1×
“Bmi1 is known as a potent negative regulator of the p16 INK4a gene [9,14], and Bmi1 is over-expressed in several carcinomas [14,15,17,18] and is associated with poor survival after therapy [32].”
BackgroundValk-Lingbeek, M. E., Bruggeman, S. W. M., & van Lohuizen, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.005 · Cited by 743
Bmi1, stem cells, and senescence regulation
Park, I.-K., Morrison, S. J., & Clarke, M. F. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420800 · Cited by 495 · cited 1×
“Bmi1 is known as a potent negative regulator of the p16 INK4a gene [9,14], and Bmi1 is over-expressed in several carcinomas [14,15,17,18] and is associated with poor survival after therapy [32].”
Background
Cited by
Critical roles of non-histone protein lysine methylation in human tumorigenesis
Hamamoto, R., Saloura, V., & Nakamura, Y. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3884 · Cited by 376
Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Ustun, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 356
Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer
Kim, W., Bird, G. H., Neff, T., Guo, G., Kerenyi, M. A., Walensky, L. D., & Orkin, S. H. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1331 · Cited by 338
Pathological classification of intrahepatic cholangiocarcinoma based on a new concept
Nakanuma, Y. (2010) · World Journal of Hepatology · doi:10.4254/wjh.v2.i12.419 · Cited by 335
Self-citationRegulation and Role of EZH2 in Cancer
Yamaguchi, H., & Hung, M.-C. (2014) · Cancer Research and Treatment · doi:10.4143/crt.2014.46.3.209 · Cited by 287
Cellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
Nakanuma, Y., Zen, Y., & Portmann, B. C. (2012) · MacSween's Pathology of the Liver · doi:10.1016/b978-0-7020-3398-8.00010-6 · Cited by 56
Self-citationMAD2L1 Functions As a Novel Diagnostic and Predictive Biomarker in Cholangiocarcinoma
Gao, Y., Liu, Y., Sun, L., Ouyang, X., Zhu, C., & Qin, X. (2021) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2021.0122 · Cited by 9
“…abnormal expression of enhancer of zeste homolog 2 (EZH2) is associated with tumorigenesis and progression in a number of different malignancies, including cholangiocarcinoge-nesis, prostate cancer, and nonsmall cell lung carcinoma (Sasaki et al. , 2008; Ren et al. , 2012; Behrens et al. , 2013).”
Metadata
- Authors
- Sasaki, M., Yamaguchi, J., Itatsu, K., Ikeda, H., & Nakanuma, Y.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2008-04-07
- Volume
- 215
- Issue
- 2
- Pages
- 175-183
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2075476449
- Cited by
- 106
- References
- 8
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.